Care Tracking for Genetic Cancer Syndromes

This trial aims to help women with high-risk genetic mutations linked to breast and ovarian cancer manage their health better and reduce their cancer risk. Initially, the study involves interviews to develop a user-friendly digital app called ACT-GEN, followed by testing the app's effectiveness. It seeks women who are aware of specific genetic mutations in genes like BRCA1/2 or Lynch syndrome genes, speak English or Spanish, and have a compatible smartphone. As an unphased trial, participants can contribute to innovative research that may improve health management tools for those at risk.

The trial information does not specify whether you need to stop taking your current medications. However, if you are actively being treated for cancer with cytotoxic therapy, you may not be eligible to participate.

Research shows that ACT-GEN, the treatment used in this study, focuses on genetic testing for hereditary cancer syndromes. Most people find genetic testing easy to handle. It involves examining DNA from a blood sample to detect genetic changes that might increase cancer risk. No major side effects have been reported from the testing process itself.

Researchers are excited about the Care Tracking for Genetic Cancer Syndromes trial because it aims to revolutionize patient care with a personalized digital approach. Unlike traditional treatments that focus solely on physical interventions like surgery, chemotherapy, or radiation, this study is developing and testing a patient-centered digital application designed to enhance ongoing care and monitoring. By integrating patient feedback into its design, the application promises to tailor support and tracking for individuals with genetic cancer syndromes, potentially leading to better outcomes and more personalized care management.

Research has shown that screening for cancers such as breast, colon, or cervical cancer can lead to better outcomes and lower risks. Studies have found that genetic testing for inherited cancer conditions is crucial for identifying individuals at higher risk. This identification aids in planning regular check-ups and preventive measures. In this trial, the ACT-GEN treatment is designed to help patients adhere to these guidelines. Although detailed data on ACT-GEN's effects remain limited, genetic testing in general has proven to significantly enhance the monitoring and early detection of cancer risks.¹⁶⁷⁸⁹